Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB-100 in Low or Intermediate-1 Risk MDS
NCT03886662Phase 2Recruiting
- Sponsor
- Lixte Biotechnology Holdings, Inc.
- Start
- Apr 2019
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of LB-100 in myelodysplastic syndrome (MDS), sponsored by Lixte Biotechnology Holdings, Inc. Primary endpoints: Number of patients with adverse events related to the study treatment and Best overall response rate at Cycle 6. Started Apr 2019; status: recruiting.
02
Drugs
LB-100
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03886662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03886662.